<DOC>
	<DOC>NCT02533375</DOC>
	<brief_summary>The primary objective is to investigate efficacy, safety and pharmacokinetics of adalimumab in Japanese subjects with generalized pustular psoriasis (GPP).</brief_summary>
	<brief_title>Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Diagnosis of generalized pustular psoriasis Total skin score of at least 3 and erythema with pustule at the Baseline in Japan Dermatology Association (JDA) severity index of Generalized Pustular Psoriasis (GPP) in GPP Medical Care Guideline 2014 in Japan Inadequate response to, or intolerance to, or contraindication to the approved GPP treatment (excluding infliximab) Infliximab secondary failure, or intolerant to infliximab Erythrodermic psoriasis, guttate psoriasis or subcorneal pustular dermatosis Druginduced GPP Cannot stop ongoing use of prohibited GPP treatments Total JDA severity index of GPP of 14 or more</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
</DOC>